Vascular endothelial growth factor (VEGF) is a principal mediator of neovascularization in wet age-related macular degeneration (AMD) and diabetic macular edema. It induces angiogenesis and increases vascular permeability and inflammation. VEGF inhibitors reduce leakage from blood vessels, prevent proliferation of new abnormal vessels, decrease swelling of the retina, and improve visual acuity in patients with neovascular (wet) AMD and diabetic macular edema.1,2 These drugs are given as periodic intravitreal injections with topical anesthesia (Table).
VEGF Inhibitors for AMD and Diabetic Macular Edema. JAMA. 2015;314(20):2184-2185. doi:10.1001/jama.2015.15427